Prospective multicenter real-world RAS mutation comparison between OncoBEAM-based liquid biopsy and tissue analysis in metastatic colorectal cancer

[1]  Aneeya K. Samantara,et al.  Advantages and Challenges , 2020 .

[2]  Hwan-Mook Kim,et al.  Perspective on Cancer Therapeutics Utilizing Analysis of Circulating Tumor Cells , 2018, Diagnostics.

[3]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[4]  N. Normanno,et al.  RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Tabernero,et al.  Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: an expert taskforce review , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  O. Rosen,et al.  1473OEncouraging activity of novel pan-KIT and PDGFRα inhibitor DCC-2618 in patients (pts) with Gastrointestinal Stromal Tumor (GIST) , 2017 .

[7]  I. Brandslund,et al.  Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. , 2017, The oncologist.

[8]  M. Ychou,et al.  Clinical utility of circulating DNA analysis for rapid detection of actionable mutations to select metastatic colorectal patients for anti-EGFR treatment , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  F. Coulet,et al.  The Role of BEAMing and Digital PCR for Multiplexed Analysis in Molecular Oncology in the Era of Next-Generation Sequencing , 2017, Molecular Diagnosis & Therapy.

[10]  P. Laurent-Puig,et al.  Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study) , 2017, Clinical Cancer Research.

[11]  C. la Vecchia,et al.  European cancer mortality predictions for the year 2017, with focus on lung cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  J. Albanell,et al.  Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  R. Salazar,et al.  Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  S. Fox,et al.  Blood‐based detection of RAS mutations to guide anti‐EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue‐based RAS testing , 2017, Molecular oncology.

[15]  D. Shelton,et al.  Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  W. Scheithauer,et al.  FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. , 2016, The Lancet. Oncology.

[17]  R. Schilsky,et al.  Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Peng,et al.  Preoperative transarterial chemoembolization for resectable hepatocellular carcinoma in Asia area: a meta-analysis of random controlled trials , 2016, Scandinavian journal of gastroenterology.

[19]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  V. Moreno,et al.  Nanofluidic Digital PCR and Extended Genotyping of RAS and BRAF for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies , 2016, Molecular Cancer Therapeutics.

[21]  R. Schilsky,et al.  Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 Summary. , 2016, Journal of oncology practice.

[22]  R. Luthra,et al.  Next-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and Challenges , 2015, Cancers.

[23]  Marc Peeters,et al.  Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer , 2015, Clinical Cancer Research.

[24]  R. Strausberg,et al.  Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  C. Bokemeyer,et al.  FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, European journal of cancer.

[26]  Chloe E Atreya,et al.  Expanded RAS: refining the patient population. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  E. Dequeker,et al.  External quality assessment unravels interlaboratory differences in quality of RAS testing for anti-EGFR therapy in colorectal cancer. , 2015, The oncologist.

[28]  Sabine Tejpar,et al.  Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  P. Angenendt,et al.  Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Wiese,et al.  Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  Bruno Landi,et al.  Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy , 2014, Clinical Cancer Research.

[32]  James D. Murphy,et al.  Colon cancer, version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[33]  J. Tabernero,et al.  Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. , 2013, The New England journal of medicine.

[34]  S. Sleijfer,et al.  KRAS and BRAF mutation status in circulating colorectal tumor cells and their correlation with primary and metastatic tumor tissue , 2013, International journal of cancer.

[35]  A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens , 2012, British Journal of Cancer.

[36]  H. Lee,et al.  Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer , 2012, BMC Cancer.

[37]  Yoko Yamamoto,et al.  Heterogeneity of KRAS Status May Explain the Subset of Discordant KRAS Status Between Primary and Metastatic Colorectal Cancer , 2011, Diseases of the colon and rectum.

[38]  K. Schaefer,et al.  Prevalence and Heterogeneity of KRAS, BRAF, and PIK3CA Mutations in Primary Colorectal Adenocarcinomas and Their Corresponding Metastases , 2010, Clinical Cancer Research.

[39]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[40]  S. Veronese,et al.  Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[42]  J. Berlin,et al.  The epidermal growth factor receptor as a target for colorectal cancer therapy. , 2005, Seminars in oncology.